Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Inc (NASDAQ:SGMO) reported its first quarter 2026 financial results on May 14, 2026, and the numbers fell short of analyst expectations. The genomic medicine company posted revenue of $1.44 million for Q1 2026, significantly below the consensus estimate of $34.4 million. On the …

Sangamo Therapeutics Inc. (SGMO) on Thursday reported a loss of $31 million in its first quarter.

Get real-time Sangamo Therapeutics Inc (SGMO) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

See the latest Sangamo Therapeutics Inc stock price (SGMO:PINX), related news, valuation, dividends and more to help you make your investing decisions.

Sangamo Therapeutics reported a consolidated net loss of $31.0 million, or $0.08 per share, for the quarter ended March 31, 2026, with revenues of $1.4 million. Total operating expenses were $33.4 million for the quarter and cash and cash equivalents were $27.6 million as of March 31, 2026.